(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.
The global gaucher and pompe diseases enzyme replacement therapy (ERT) market is poised for remarkable growth, with projections indicating a surge from USD 3.3 billion in 2023 to an impressive USD 6.2 ...
Hello, and welcome to Virtual Investor Conferences. My name is John Viglotti, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you joined us for our next ...